

1 Neurofilament light protein as a blood 2 biomarker for Huntington's disease in 3 children

4
5 Lauren M Byrne^{1*†}, Jordan L Schultz^{2†}, Filipe B Rodrigues¹, Ellen van der Plas²,

6 Douglas Langbehn², Peg Nopoulos^{2††}, Edward J Wild^{1*††}

7

8 Affiliations:

9 1. Huntington's Disease Centre, UCL Queen Square Institute of Neurology,

10 University College London, London WC1N 3BG

11 2. Department of Psychiatry, Carver College of Medicine at the University of Iowa,

12 200 Hawkins Drive, Iowa City, IA 52242

13

14

15 † These authors contributed equally as first authors of this study.

16 †† These authors contributed equally as senior authors of this study

17 * Corresponding authors: lauren.byrne.14@ucl.ac.uk; e.wild@ucl.ac.uk;

18

19

20 Current main text Word count: 18003

21

22 Abstract

23 Juvenile-onset Huntington's disease (JoHD) is a rare, particularly devastating form of
24 Huntington's Disease (HD) for which clinical diagnosis is challenging and robust
25 outcome measures are lacking. Neurofilament light protein (NfL) in plasma has
26 emerged as a prognostic biomarker for adult-onset HD. We report that plasma NfL is
27 elevated in JoHD and premanifest HD mutation-carrying children. Quantifying plasma
28 NfL may improve clinical diagnosis and therapeutic trial design in the pediatric
29 population.

30

31 Main text

32 Juvenile-onset HD (JoHD) is a devastating form of Huntington's Disease (HD) that
33 manifests before the age of 21¹. While the underlying pathology of CAG repeat
34 expansions in *HTT* exon 1 is similar to adult-onset HD (AoHD), JoHD has typically much
35 larger expansions. JoHD has unique disease features including prominent rigidity,
36 dystonia, and bradykinesia, and tends to progress rapidly. There are no disease-
37 modifying therapies for HD but numerous targeted therapeutics are in advanced trials².
38 JoHD is ultra-rare (approximately 5 per million³), contributing to a lack of robust clinical
39 scales or biomarkers that could facilitate clinical trials in this population. Further, initial
40 manifestations of JoHD often overlap with normal variability in childhood or
41 adolescence, or with prevalent juvenile disorders such as depression, anxiety, ADHD,
42 Tourette's syndrome, complicating difficult decisions about diagnosis and genetic
43 testing of minors¹.

44
45 Similar to other neurological diseases, plasma neurofilament light chain protein (NfL)
46 has emerged as a biomarker for AoHD that strongly correlates with clinical, cognitive
47 and MRI measures⁴. Baseline plasma NfL concentration increases early and predicts
48 subsequent HD progression and brain atrophy⁴⁻⁷. In a cohort of young adult premanifest
49 HD (preHD) mutation carriers, on average 24 years from estimated onset, NfL
50 concentrations in CSF and plasma were the earliest detectable alterations in HD⁸.

51
52 Despite being a robust biomarker for AoHD⁴⁻⁷, NfL has yet to be evaluated in JoHD or
53 in children and adolescent HD mutation carriers who will develop HD in adulthood but

54 have no disease manifestations (preHD). We quantified plasma NfL in a unique cohort
55 of 9 JoHD subjects, 30 preHD and 61 mutation-free control children and adolescents.
56
57 Characteristics of the age-matched cohort are in Supplementary Table 1. We assessed
58 potential confounding demographics (age: Extended Data Fig. 1a; parental
59 socioeconomic status: Extended Data Fig. 1b; sex: Extended Data Fig. 1c; Tanner
60 stage [puberty classification system]: Extended Data Fig. 1d), finding little evidence for
61 the impact of healthy development on plasma NfL concentrations.
62
63 We investigated whether plasma NfL was elevated in JoHD. JoHD patients had
64 significantly higher plasma NfL than controls (32.46 pg/mL, [95% Confidence interval
65 (95%CI) 18.08 – 58.27], versus 4.76 pg/mL, [95%CI 4.33 – 5.23] respectively;
66 $p < 0.0001$; Fig. 1a). In JoHD, plasma NfL rose with age on a trajectory significantly
67 distinct from controls (Age*Group: 1.09 pg/mL/year [Confidence interval (95%CI) 1.02-
68 1.16], $p = 0.013$; Fig. 1b). A cutoff of 11.1 pg/mg identified 91% of JoHD cases and 96%
69 of controls (AUC 0.96; Fig. 1c). We also evaluated the relationship between plasma NfL
70 and JoHD clinical measures (Supplementary Table 2). There were no associations
71 between plasma NfL and UHDRS total motor scale, the JoHD Motor scale, or its
72 components, with the exception of the Bradykinesia Drinking measure which had a
73 positive association with plasma NfL (LMER Est. 1.25, [95%CI 0.46 – 2.05] $p = 0.017$).
74 However, this did not survive multiple comparisons correction (false discovery rate
75 $p = 0.103$). There was a significant, positive association between disease duration and
76 plasma NfL concentration (LMER Est. 2.18 [95%CI 0.31 – 4.05] $p = 0.045$). No significant

77 associations were found between plasma NfL and disease burden score (DBS) or brain
78 volumes in JoHD.


79

80 Next, we investigated plasma NfL in preHD children. Overall, the age trajectories of NfL
81 in preHD compared to healthy controls were not statistically different from one another
82 (Age*group: 1.02 pg/mL/year [95%CI 0.97-1.06], $p=0.534$; Fig. 1d). We subdivided
83 preHD by their predicted years to onset (YTO) to assess whether plasma NfL was
84 elevated in children closer to their predicted onset. The characteristics of the YTO
85 groupings are presented in Supplementary Table 3. The mean plasma NfL
86 concentration in controls was 4.76 pg/mL, (95%CI 4.33 – 5.23), which did not differ
87 significantly from preHD 40-60 YTO (5.21 pg/mL, [95%CI 3.96 – 6.84]), 30-40 YTO
88 (4.53 pg/mL, [95%CI 3.45 – 5.94]), or 20-30 YTO (4.10 pg/mL, [95%CI 3.32 – 5.05]).
89 However, the preHD groups that were 15-20 years from onset (7.03 pg/mL [95%CI 5.34
90 – 9.25]) and within 15 years from predicted onset (10.07 pg/mL [95%CI 7.51 – 13.52])
91 both had significantly higher plasma NfL than controls ($t=3.31$, $p_{FDR}=0.0033$ and $t=3.72$,
92 $p_{FDR}=0.0015$, respectively; Fig. 1e).

93

94 In a combined group of HD mutation carriers (preHD+JOHD), we explored the
95 relationship between plasma NfL and brain volume, including whole brain, caudate and
96 putamen volume, which are of primary pathological importance in HD. There were
97 significant negative associations (Supplementary Table 4; Fig. 1f-h) between plasma
98 NfL and whole-brain (LMER Est. -0.90 [CI -1.64 – -0.16] $p=0.020$; Fig. 1f), caudate
99 (LMER Est. -0.06 [95%CI -0.08 – -0.03] $p=0.0001$; Fig. 1g) and putamen volumes

100 (LMER Est. -0.09 [95%CI -0.12 – -0.06] $p < 0.0001$; Fig. 1h). When exploring at the
101 associations limiting the analysis to JoHD and preHD children within 20 years from
102 predicted motor onset, the respective slopes of these associations were greater but,
103 given the reduced sample size, only caudate (LMER Est. -0.12 [95%CI -0.18 – -0.05]
104 $p = 0.0040$; Fig. 1g) and putamen (LMER Est. -0.14 [95%CI -0.21 – -0.07] $p = 0.0025$; Fig.
105 1h) volumes remained significant (Supplementary Table 4).




106

107 *Fig. 1 Plasma NfL in JoHD and children at-risk for HD.*

108 *a, Plasma NfL groupwise differences and b, modelled plasma NfL trajectories with age in JoHD compared to controls.*
 109 *c, Receiver operating characteristic curve for Plasma NfL discriminating JoHD from controls. d, modelled plasma NfL*
 110 *trajectories with age in preHD and e, YTO groupwise plasma NfL differences compared to control children. Plasma*
 111 *NfL associations with f, whole brain g, caudate and h, putamen volumes in all HD mutation carriers or those with*
 112 *JoHD and within 20 YTO. Data points are raw plasma NfL. Statistics were generated from LMER models with effects*
 113 *per participant and per family (intercepts) and using Satterthwaite approximation for degrees of freedom. P values in*
 114 *e are adjusted for multiple comparisons. For f-h, all brain volumes were %ICV; models additionally included a*
 115 *covariate to account for different scanners; and model statistics are presented in Supplementary Table 4. NfL,*
 116 *neurofilament light protein; JoHD, Juvenile-onset Huntington's disease; preHD, premanifest HD; YTO, years to onset;*
 117 *ICV, intracranial volume; LMER, linear mixed effects regression; MD, mean difference.*

118

119 We combined the KidsHD and KidsJoHD cohorts with HD-CSF – a longitudinal cohort of
120 80 adult HD mutation carriers and controls – to compare the course of plasma NfL
121 throughout life in health, JoHD and adult-onset Huntington’s disease (Fig. 2a). Plasma
122 NfL initially begins to rise from approximately DBS 200.



123

124 *Fig. 2 Plasma NfL throughout the HD mutation carrier lifespan.*

125 *Plasma NfL plotted against a. age and b. disease burden score in both the Kids cohort and HD-CSF cohort. Data*
126 *points are raw plasma NfL. NfL, neurofilament light protein.*

127

128 The elevation and distinct age trajectory of plasma NfL in JoHD patients compared to
129 healthy control children are consistent with those observed in adult onset HD^{4,6,7}.
130 Associations with clinical measures were modest, although this may be driven by lack of
131 power and limitations in JoHD clinical measures. Furthermore, as previously reported in
132 AoHD⁴⁻⁷, plasma NfL was inversely associated with brain volumes in children with HD
133 mutations, whether JoHD or preHD. Plasma NfL elevation in preHD children within 20
134 years from predicted onset is consistent with increases reported in a young adult HD
135 cohort. Morphological neurodevelopment differences in the striatum⁹ may limit the utility
136 of MRI to distinguish between the neurodevelopmental and neurodegeneration effects
137 of the HD mutation. NfL could provide insights into the point where neurodevelopment is
138 the predominant concern, potentially helping to inform decisions around the timing of
139 disease-modifying interventions Collectively, these findings suggest two potential
140 applications of NfL: 1) identification of high-risk children for early diagnosis and
141 intervention; and 2) assessing neuroprotection in cohorts of all ages. By evaluating NfL
142 across a wide age range, we can begin to estimate plasma NfL thresholds indicative of
143 neurodegeneration. This could be of value in informing ethically-challenging decisions
144 about which at-risk children showing possible disease manifestations should undergo
145 genetic testing. We conclude that plasma NfL shows promise as a blood biomarker of
146 JoHD and may facilitate clinical trial design in this rare and understudied population.

147


148

149 References

- 150 1. Oosterloo, M., Bijlsma, E. K., de Die-Smulders, C. & Roos, R. A. C. Diagnosing
151 Juvenile Huntington's Disease: An Explorative Study among Caregivers of
152 Affected Children. *Brain Sci.* **10**, 155 (2020).
- 153 2. Tabrizi, S. J., Flower, M. D., Ross, C. A. & Wild, E. J. Huntington disease: new
154 insights into molecular pathogenesis and therapeutic opportunities. *Nature*
155 *Reviews Neurology* vol. 16 529–546 (2020).
- 156 3. Quarrell, O., O'Donovan, K. L., Bandmann, O. & Strong, M. The prevalence of
157 juvenile Huntington's disease: A review of the literature and meta-analysis. *PLoS*
158 *Currents* vol. 4 (2012).
- 159 4. Byrne, L. M. *et al.* Neurofilament light protein in blood as a potential biomarker of
160 neurodegeneration in Huntington's disease: a retrospective cohort analysis.
161 *Lancet Neurol.* **16**, 601–9 (2017).
- 162 5. Johnson, E. B. *et al.* Neurofilament light protein in blood predicts regional atrophy
163 in Huntington disease. *Neurology* **90**, e717–e723 (2018).
- 164 6. Byrne, L. M. *et al.* Evaluation of mutant huntingtin and neurofilament proteins as
165 potential markers in Huntington's disease. *Sci. Transl. Med.* **10**, eaat7108 (2018).
- 166 7. Rodrigues, F. B. *et al.* Mutant huntingtin and neurofilament light have distinct
167 longitudinal dynamics in Huntington's disease. *Sci. Transl. Med.* **12**, 2888 (2020).
- 168 8. Scahill, R. I. *et al.* Biological and clinical characteristics of gene carriers far from
169 predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a
170 cross-sectional analysis. *Lancet Neurol.* **19**, 502–512 (2020).
- 171 9. van der Plas, E. *et al.* Abnormal brain development in child and adolescent

- 172 carriers of mutant huntingtin. *Neurology* **93**, E1021–E1030 (2019).
- 173 10. Tereshchenko, A. *et al.* Brain structure in juvenile-onset Huntington disease.
174 *Neurology* **92**, E1939–E1947 (2019).
- 175 11. Byrne, L. M. *et al.* Cerebrospinal fluid neurogranin and TREM2 in Huntington’s
176 disease. *Sci. Rep.* **8**, 4260 (2018).
- 177 12. Lowe, A. J. *et al.* Cerebrospinal fluid endo-lysosomal proteins as potential
178 biomarkers for Huntington’s disease. *PLoS One* **15**, (2020).
- 179 13. Horton, M. C. *et al.* Assessment of the Performance of a Modified Motor Scale as
180 Applied to Juvenile Onset Huntington’s Disease. *J. Huntingtons. Dis.* **8**, 181–193
181 (2019).
- 182 14. Penney, J. B., Vonsattel, J.-P., Macdonald, M. E., Gusella, J. F. & Myers, R. H.
183 CAG repeat number governs the development rate of pathology in Huntington’s
184 disease. *Ann. Neurol.* **41**, 689–692 (1997).
- 185 15. Langbehn, D., Brinkman, R., Falush, D., Paulsen, J. & Hayden, M. A new model
186 for prediction of the age of onset and penetrance for Huntington’s disease based
187 on CAG length. *Clin. Genet.* **65**, 267–277 (2004).
- 188 16. Khalil, M. *et al.* Serum neurofilament light levels in normal aging and their
189 association with morphologic brain changes. *Nat. Commun.* **11**, 1–9 (2020).
- 190

191 Extended Data



192

193 *Extended Data Fig. 1 Plasma NfL in healthy development and potential confounding demographics.*

194 *Plasma NfL concentrations are plotted against a, age b, parental socioeconomic status c, sex and d, Tanner stage*
195 *(puberty) in healthy control individuals (n=61). Data was available from multiple timepoints for some individuals (83*
196 *observations). P-values were generated from linear mixed effects regression models with a random participant effect*
197 *(intercept). Pairwise tests were post-hoc t-tests using Satterthwaite's method. Raw NfL values are presented. Models*
198 *used natural log transformed NfL data and was back-transformed for a, the age model. NfL, neurofilament light*
199 *protein; LMER, linear mixed effects regression.*

200

201

202

203 Acknowledgements

204 We would like to thank all the participants who took part, providing their time, data and
205 samples to make this work possible.

206 Funding

207 This work was supported by the Medical Research Council UK (to EJW), the CHDI
208 Foundation (to EJW), the Huntington's Disease Society of America (to LMB), the
209 Hereditary Disease Foundation (to LMB), and the National Institute of Health (NIH)
210 grant NS094387 Growth and Development of the Striatum in Huntington's Disease (to
211 PN).

212 Author Contributions

213 EJW, PN, LMB, JLS and DL were responsible the conception and design of the work;
214 LMB, JLS, FBR and EVP were involved in the acquisition of data; LMB and JLS
215 performed the data analysis; EJW, PN, LMB, JLS and DL were involved in the
216 interpretation of data; LMB drafted the first manuscript draft with JLS and incorporated
217 coauthor revisions. All authors approved the submitted version of the manuscript

218 Competing Interests statement

219 LMB, FBR and EJW are full-time UCL employees. LMB receives salary support from the
220 Huntington's disease Society of America, and has provided consultancy for F.
221 Hoffmann-La Roche AG, Genentech, Novartis International AG, Annexon Inc and GLG.
222 JLS receives salary support from the National Center for Advancing Translational
223 Sciences (NIH KL2TR002536) and the Michael J. Fox Foundation for Parkinson's
224 Research. FBR receives salary support from CHDI Foundation, and has provided

225 consultancy to GLG and Roche. E.J.W. reports grants from Medical Research Council
226 UK, CHDI Foundation, and F. Hoffmann–La Roche Ltd. during the conduct of the study
227 and personal fees from F. Hoffman–La Roche Ltd., Triplet Therapeutics, PTC
228 Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda
229 Pharmaceuticals Ltd., and Loqus23. All honoraria for these consultancies were paid
230 through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University
231 College London. University College London Hospitals NHS Foundation Trust has
232 received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals,
233 Pfizer, and Teva Pharmaceuticals. and Stroke, the CHDI Foundation, University College
234 of London, and from the Wellcome Trust. During the past 12 months, he has served as
235 a paid statistical consultant for the design of Huntington’s Disease trials for Novartis AG,
236 Voyager Therapeutics, Spark therapeutics, and Takeda Pharmaceutical Company
237 Limited. He has also been a paid consultant to Trinity Life Sciences. PN and EVP report
238 no competing interests.
239

240 Online methods

241 Study design

242 This retrospective analysis involved quantification of plasma NfL using available blood
243 samples and matching phenotypic data that were collected as part of the KidsHD and
244 KidsJoHD studies – observational studies at the University of Iowa that recruited
245 children and young adults with a family history of HD or with Juvenile Onset HD
246 respectively; as well as healthy control volunteers with no known family history of HD.
247 Recruitment began in May 2009 and was completed in January 2018. All KidsHD/JoHD
248 participants provided either saliva or blood for genetic testing which was for research
249 purposes only; results were not revealed to participants, their families, clinicians, or
250 researchers. Both studies implemented an accelerated longitudinal design where some
251 participants attended multiple visits at 1-2 year intervals and so had repeated measures
252 as previously described^{9,10}. The Institutional Review Board at the University of Iowa
253 approved the KidsHD and KidsJoHD studies. The parents or guardians of participants
254 who were less than 18 years old provided written consent and the children provided
255 written assent. Participants who were 18 years or older provided written consent.
256 We combined plasma NfL data from both KidsHD and KidsJoHD with previously
257 published plasma NfL data from the longitudinal HD-CSF cohort to visually assess how
258 NfL fluctuates over the lifespan of the HD mutation carrier. HD-CSF has been
259 extensively described^{6,11,12} (online protocol: DOI: 10.5522/04/11828448.v1).

260 Participants

261 For the current analysis, at-risk participants from Kids-HD were classified as
262 premanifest HD (preHD) mutation carriers if their CAG repeat length was ≥ 36 and
263 healthy controls if <36 . JoHD was defined as a UHDRS Total Motor Score ≥ 10 before
264 the age of 21 in the context of the HD mutation and a confirmed diagnosis by a trained
265 neurologist. Plasma samples were available for 30 preHD (44 visits), 60 healthy controls
266 (82 visits) and nine JoHD participants (11 total visits). Clinical severity in JoHD was
267 assessed using the UHDRS total motor score, the JoHD Motor scale¹³ – an adapted
268 version of UHDRS total motor score which weighs JoHD-specific components higher –
269 and disease duration (determined by length of time from clinical diagnosis to time of
270 study visit in years). Disease burden score (DBS) – an arithmetic composite of CAG and
271 age that encompasses the cumulative burden of the CAG expansion [Age * (cAG-35.5)]
272 – was used as a known predictor of HD progression¹⁴.

273 The preHD group was divided into subgroups based on their predicted years to motor
274 onset (YTO) into the following groups: 40-60 YTO; 30-40 YTO; 20-30 YTO; 15-20 YTO;
275 <15 YTO. This was calculated using the using their CAG repeat length and age in the
276 formula from Langbehn and colleagues¹⁵.

$$277 \quad YTO = Age_n - (21.54 + e^{(9.556 - [0.1460 * CAG])})$$

278 This formula was used only for participants with a CAG repeat length of 36-49. For
279 participants with a CAG repeat length of 50 or above, the Langbehn formula was slightly
280 modified to provide a more accurate estimate of the predicted years to onset.
281 Participants were excluded from either study if they had a history of a major neurologic
282 illness, brain surgery, or significant head trauma.

283

284 Plasma Sample Collection and Storage

285 KidsHD/JoHD blood samples were collected in EDTA Vacutainer tubes (BD). All
286 samples were coded with a unique study ID and were sent to the University of Iowa
287 Diagnostic Laboratories. Samples were briefly stored on ice and then centrifuged at
288 2,000g for x minutes. Plasma was decanted before being centrifuged at 3,000g at 4°C
289 for 15 minutes then pipetted into 1.2-mL cryotubes in 500 uL aliquots and frozen and
290 stored at -80°C before being shipped.

291

292 NfL Quantification

293 KidsHD/JoHD plasma NfL concentrations were measured using the commercially
294 available NF-Light® assay kit from on the Simoa HD-1 analyzer platform as per the
295 manufacturer's instructions (Quanterix, Lexington). NfL was quantified in duplicate for all
296 plasma samples. The intra-assay coefficient of variation (CV) was 6.5% and inter-assay
297 CV was 1.65%. HD-CSF plasma NfL was previously quantified and published as per
298 Rodrigues et al⁷.

299

300 Image Acquisition and processing

301 The structural imaging acquisition methods have been described previously⁹. A 3T
302 Siemens Trio TIM (Siemens AG, Munich, Germany) machine was used to acquire
303 images prior to June 2016 (n=33). After June 2016, a 3T General Electric Discovery
304 MR750w (GE Medical Systems, Chicago, IL) was used (n=17). Full details regarding
305 image processing have been previously described by van der Plas, et al⁹.

306

307 Statistical Analysis

308 In accordance with previous evaluations of plasma NfL, all available NfL concentrations
309 underwent natural log-transformation to account for non-normal distribution^{4,6}. We
310 assessed potentially confounding demographics and measures of healthy
311 development on plasma NfL. None of the variables assessed had an effect on plasma
312 NfL. However, since NfL has been shown to be associated with healthy aging, we
313 included age as a covariate for subsequent analyses¹⁶. For the primary analyses-of-
314 interest, we performed linear mixed effects regression (LMER) models. The accelerated
315 longitudinal design of KidsHD/JoHD allows for modeling trajectories of development
316 over time while statistically accounting for the correlation that occurs from repeat visits
317 from individuals⁹. All LMER models also included random effects per family to account
318 for siblings in the dataset. P-values were estimated using Satterthwaite approximation
319 for degrees of freedom throughout.

320

321 For groupwise comparisons, we compared LMER model adjusted mean plasma NfL
322 values between groups. In these models, within-subject and residual variances were
323 estimated separately for the various groups via iteratively re-weighted least squares.
324 This was done to account for sizable differences in variation between the groups. We
325 adjusted for multiple comparisons using false-discovery-rate (FDR) corrections.

326

327 The age*group interaction was evaluated to determine group differences in age-
328 trajectories of plasma NfL. To assess associations with clinical measures, LMER

329 models were constructed with plasma NfL as the independent variable and clinical
330 measures as the dependent variables. LMER models for DBS – a predictor of HD
331 progression – included NfL as the dependent variable. Age was not included as a
332 covariate in either of the models that investigated the relationship between disease
333 duration or DBS and plasma NfL to avoid collinearity, since age was used to calculate
334 these variables. For neuroimaging measures, brain volumes were the dependent
335 variables and NfL independent within the LMER models to permit the addition of
336 scanner as a covariate to account for scanner differences. All brain volumes were
337 presented as percent of intracranial volume (ICV).

338
339 We created a receiver operating characteristic curve by performing a generalized
340 binomial regression model with plasma NfL as the independent predictor variable for
341 whether or not a participant was a healthy control or had JoHD. We calculated
342 Youden's Index by adding the sensitivity and specificity at all available plasma NfL
343 levels. The maximal specificity cutoff point was at 0.964 and the maximal sensitivity
344 cutoff point was at 0.909 and this point correlated with a plasma NfL cutoff point of 11.1
345 pg/mL. These analyses were performed using the pROC package in RStudio (version
346 1.16.2)

347
348 Groupwise analyses were performed using the PROC MIXED function within SAS (v9.4,
349 SAS Institute Inc, Cary, NC, USA). All other models were performed in RStudio version
350 1.3.159 using the lmerTest version 3.1.

351 [Data availability](#)

352 The data that support the findings of this study are available from the corresponding
353 author upon reasonable request.

354

355 Supplementary material

356 *Supplementary Table 1 Baseline Cohort Characteristics of KidsHD and KidsJoHD*

357 *P-values for continuous variables were generated from one-way analyses of variance. P-values for categorical*
 358 *variables were generated from Pearson Chi-Square analyses. Values are presented as mean ± SD unless otherwise*
 359 *stated. preHD, premanifest Huntington's disease; JoHD, Juvenile-onset Huntington's disease. SD, Standard*
 360 *deviation; CAG, Cytosine-Adenine-Guanine; BMI, Body mass index; SES, socioeconomic status, measured by the*
 361 *Hollingshead Scale; NfL, neurofilament light protein.*

	Controls	preHD	JoHD	P-Value
N (total visits)	61 (83)	30 (44)	9 (11)	N/A
Age	12.75 ± 3.71	14.00 ± 3.12	16.48 ± 6.38	0.40
Males, N (%)	23 (37.7)	10 (33.3)	5 (55.6)	0.483
CAG	20.33 ± 4.39	43.90 ± 4.47	72.11 ± 12.67	<0.0001
BMI	22.14 ± 7.48	21.92 ± 5.13	21.51 ± 6.22	0.963
Tanner Stage, N (%)				0.337
0	15 (22.2)	4 (13.3)	2 (22.2)	
1	4 (6.6)	0 (0)	0 (0)	
2	4 (6.6)	1 (3.3)	0 (0)	
3	12 (19.7)	5 (16.7)	0 (0)	
4	16 (26.2)	15 (50.0)	4 (44.4)	
5	10 (16.4)	5 (16.7)	3 (33.3)	
Parental SES, N (%)				0.062
1	0 (0)	0 (0)	0 (0)	
2	36 (59.0)	14 (46.7)	2 (22.2)	
3	22 (36.1)	14 (46.7)	4 (44.4)	
4	2 (3.3)	2 (6.7)	2 (22.2)	
5	1 (1.6)	0 (0)	1 (11.1)	
Plasma NfL (pg/mL)	4.71 ± 1.55	5.05 ± 1.57	35.16 ± 2.95	<0.0001

362

363

364

365

366

367

368

369

370

371

372 *Supplementary Table 2 Clinical measures and their associations with plasma NfL in JoHD*

373 *P-values were generated from linear mixed effects regression models with effects per participant and per family*
 374 *(intercepts) and using Satterthwaite approximation for degrees of freedom. Values are presented as the beta*
 375 *estimate of the model relative to the log-transformed plasma NfL concentration. The models that assessed the*
 376 *relationship between disease duration and disease burden score did not include age as a covariate, as both*
 377 *independent variables are calculated using age. All brain volumes were corrected for intracranial volume and models*
 378 *investigating the relationship between plasma NfL and brain volumes included a covariate to account for different*
 379 *scanners. NfL, neurofilament light protein; UHDRS, Unified Huntington's Disease Rating Scale; TMS, total motor*
 380 *score; JoHD, Juvenile-onset Huntington's disease.*

Clinical measures	Association with plasma NfL			
	N (total visits)	Estimate	Confidence interval	P-value
UHDRS TMS	9 (11)	7.02	-13.91 – 27.94	0.522
JoHD Motor Scale	9 (11)	3.87	-0.56 – 8.30	0.119
Chorea	9 (11)	0.07	-0.57 – 0.71	0.832
Bradykinesia Handtapping	9 (11)	0.05	-0.96 – 1.05	0.934
Bradykinesia Drinking	9 (10)	1.25	0.46 – 2.05	0.017
Tremors	9 (11)	0.41	-0.38 – 1.19	0.333
Disease duration	9 (11)	1.19	0.03 – 2.35	0.045
Disease burden score	9 (11)	1.00	-0.01 – 2.01	0.347
Whole Brain Volume	9 (10)	-3.10	-7.19 – 0.99	0.180
Putamen Volume	9 (10)	-0.10	-0.20 – 0.01	0.112
Caudate Volume	9 (10)	-0.07	-0.15 – 0.01	0.116

381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395

396 *Supplementary Table 3 Baseline Cohort Characteristics by years to onset groupings*

397 *P-values for continuous variables were generated from one-way analyses of variance. P-values for categorical*
 398 *variables were generated from Pearson Chi-Square analyses. Values are presented as mean ± SD unless otherwise*
 399 *stated. SD, Standard deviation; CAG, Cytosine-Adenine-Guanine; YTO, years to onset; BMI, Body mass index; SES,*
 400 *socioeconomic status, measured by the Hollingshead Scale; NfL, neurofilament light protein.*

	Controls	40-60 YTO	30-40 YTO	20-30 YTO	15-20 YTO	<15 YTO	P-Value
N (total visits)	61 (83)	9 (15)	10 (12)	7 (9)	2 (4)	2 (4)	NA
Age	12.75 ± 3.71	13.99 ± 2.07	13.47 ± 3.93	13.33 ± 2.98	15.04 ± 2.65	17.96 ± 3.12	0.355
Female, N (%)	23 (37.7)	4 (44.4)	8 (80.0)	6 (85.7)	1 (50.0)	1 (50.00)	0.488
CAG	20.33 ± 4.39	39.78 ± 0.97	42.60 ± 0.84	46.71 ± 2.29	49.00 ± 1.41	54.00 ± 7.07	<0.0001
YTO	N/A	50.39 ± 6.23	36.38 ± 2.03	24.392 ± 2.87	17.96 ± 0.79	11.06 ± 1.93	<0.0001
BMI	22.14 ± 7.48	22.63 ± 5.88	20.68 ± 4.83	21.99 ± 4.86	18.23 ± 1.16	28.42 ± 1.30	0.295
Tanner Stage							0.280
0	15 (22.2)	0 (0.0)	3 (30.0)	1 (14.3)	0 (0.0)	0 (0.0)	
1	4 (6.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
2	4 (6.6)	1 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
3	12 (19.7)	4 (44.4)	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	
4	16 (26.2)	4 (44.4)	5 (50.0)	4 (57.1)	1 (50.0)	1 (50.0)	
5	10 (16.4)	0 (0.0)	2 (20.0)	2 (28.6)	0 (0.0)	1 (50.0)	
Parental SES, N (%)							0.366
0	0 (0)						
1	36 (59.0)	5 (55.6)	7 (70.0)	1 (14.3)	1 (50.0)	0 (0.0)	
2	22 (36.1)	3 (33.3)	3 (30.0)	5 (71.4)	1 (50.0)	2 (100.0)	
3	2 (3.3)	1 (11.1)	0 (0.0)	1 (14.3)	0 (0.0)	0 (0.0)	
4	1 (1.6)						
Plasma NfL	4.71 ± 1.55	4.81 ± 1.55	4.81 ± 1.67	4.43 ± 1.32	6.42 ± 1.48	9.97 ± 1.63	0.211

401

402

403

404

405

406

407

408

409

410

411 *Supplementary Table 4 Plasma NfL associations with brain volume in HD mutation carriers*

412 *P-values were generated from linear mixed effects regression models with random effects per participant and per*
413 *family (intercepts), age as a covariate and using Satterthwaite approximation for degrees of freedom. Values are*
414 *presented as the beta estimate of the model relative to the log-transformed plasma NfL concentration. All brain*
415 *volumes were corrected for intracranial volume and models investigating the relationship between plasma NfL and*
416 *brain volumes included a covariate to account for different scanners. NfL, neurofilament light protein; HD,*
417 *Huntington's disease; JoHD, Juvenile-onset Huntington's disease.*

Clinical measures	Association with plasma NfL - All HD mutation carriers				Association with plasma NfL – JoHD and within 20 YTO			
	N (total visits)	Estimate	Confidence interval	P-value	N (total visits)	Estimate	Confidence interval	P-value
Whole Brain Volume	35 (49)	-0.90	-1.64 – -0.16	0.020	12 (17)	-1.46	-3.67 – -0.74	0.207
Caudate Volume	35 (49)	-0.06	-0.08 – -0.03	0.0001	12 (17)	-0.12	-0.18 – -0.05	0.0040
Putamen Volume	35 (49)	-0.09	-0.12 – -0.06	<0.0001	12 (17)	-0.14	-0.21 – -0.07	0.0025

418

419

420

421

422

423

424

425

426

427

428

429

